As shown in Fig. 1h,i, targeting BCR signalling with ibrutinib or GS-1101 blocked stroma-induced β1 expression and attenuated MCL adhesion to stroma in both MCL cell lines and primary MCL cells. This evidence concerns the gene BCR and mantle cell lymphoma.